Stock Market

Twilio slumps in afterhours trading after guidance falls short of estimates

Investing | Fri, Feb 14 2025 09:59 AM AEDT

1695367561_650d4189d32c8_1692951951_64e8658fe70f4_breaking_news_600.png
Image Source: Sivastatz

Investing.com -- Twilio Inc (NYSE:TWLO) reported Thursday mixed fourth-quarter results and guidance for the current-quarter that fell short of estimates.

Twilio fell 7% in afterhours following the report.

For the three months ended Dec. 31, Twilio reported adjusted EPS of $1.00 on revenue of $1.19 billion. Analysts polled by Investing.com expected EPS of $1 on revenue of $1.17 billion.

The customer engagement platform guided Q1 adjusted EPS of $0.88 to $0.93 on revenue of $1.13B to $1.14B. Analysts polled by Investing.com expected EPS of $0.98 on revenue of $1.14B.

For 2025, the company sees non-gaap income from operations $825M to $850M.

This article first appeared in Investing.com

Market Updates

Colgate-Palmolive Company Announces Agreement to Acquire Prime100

NEW YORK--(BUSINESS WIRE)--As part of its growth strategy, which includes investing in faster-growing product segments adjacent to its ...

Business Wire | Wed, Feb 19 2025 12:00 PM AEDT

Read More
Market Updates

Coeur Reports Year-End 2024 Mineral Reserves and Resources and Provides Palmarejo Exploration Update

Substantial resource increases at Wharf and Palmarejo Kensington’s reserve-based mine life extended to five years – a doubling in three ...

Business Wire | Wed, Feb 19 2025 11:30 AM AEDT

Read More
Stock Market

Salesforce: BofA says channel checks are positive

Investing.com -- Bank of America reiterated its Buy rating on Salesforce (NYSE:CRM) with a $440 price target in a ...

Investing | Wed, Feb 19 2025 06:23 AM AEDT

Read More
World News

Sustainability as a Financial Driver: How Green Practices Boost the Bottom Line

For years, the relationship between sustainability and profitability in supply chain management was viewed as a zero-sum game. Businesses operated ...

3BL | Wed, Feb 19 2025 06:00 AM AEDT

Read More
Market Updates

Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery

The clinical study aims to evaluate a vaccine for avian influenza A (H7N9) delivered by Vaxxas’ high-density microarray patch (...

Business Wire | Wed, Feb 19 2025 05:00 AM AEDT

Read More